Per-protocol population | |||||||
---|---|---|---|---|---|---|---|
Treatment group/time-point (baseline) | Baseline-month 3 | Treatment group/time-point (crossover) | Month 3-month 6 | ||||
mm Hg ± SD | Pvalue* | n | mm Hg ± SD | Pvalue* | n | ||
Bim/tim 8 am | -4.9 ± 1.7 | 0.0073 | 30 | Dorz/brim/tim 8 am | +3.0 ± 0.4 | 0.0006 | 30 |
Bim/tim 10 am | -4.7 ± 0.2 | 0.0045 | Dorz/brim/tim 10 am | +0.2 ± 0.3 | 0.2710 | ||
Dorz/brim/tim 8 am | -3.3 ± 1.2 | <0.0001 | 26 | Bim/tim 8 am | -0.9 ± 0.8 | 0.0770 | 26 |
Dorz/brim/tim 10 am | -3.0 ± 1.0 | <0.0001 | Bim/tim 10 am | 0.0 ± 0.6 | 0.9463 | ||
Intent-to-treat population | |||||||
Treatment group/time-point (baseline) | Baseline-month 3 | Treatment group/time-point (crossover) | Month 3-month 6 | ||||
mm Hg ± SD | P value* | n | mm Hg ± SD | P value* | n | ||
Bim/tim 8 am | -4.7 ± 1.3 | <0.0001 | 41 (BL)–35 (M3) | Dorz/brim/tim 8 am | +2.9 ± 2.9 | 0.0006 | 35 (M3)–26 (M6) |
Bim/tim 10 am | -4.4 ± 0.4 | <0.0001 | Dorz/brim/tim 10 am | +0.3 ± 0.3 | 0.5940 | ||
Dorz/brim/tim 8 am | -3.1 ± 1.3 | <0.0001 | 37 (BL)–28 (M3) | Bim/tim 8 am | -0.1 ± 0.8 | 0.9286 | 28 (M3)–32 (M6) |
Dorz/brim/tim 10 am | -3.0 ± 0.0 | <0.0001 | Bim/tim 10 am | 0.0 ± 0.6 | 0.9463 |